Effect of Dipyridamole combined with IVIG and Aspirin in the treatment of children with Kawasaki disease and its effect on T lymphocyte subsets, coagulation function and inflammatory factor levels#br#
LI Hongyuan ZHANG Hui ZHANG Jianming▲
Department of Pediatrics, Fuyang Women’s and Children’s Hospital, Anhui Province, Fuyang 236000, China
Abstract：Objective To investigate the effect of Dipyridamole combined with Intravenous Immunoglobulin (IVIG) and Aspirin in the treatment of children with Kawasaki disease (KD) and its effect on T lymphocyte subsets, coagulation function, and inflammatory factor levels. Methods A total of 80 children with KD admitted to Department of Pediatrics, Fuyang Women’s and Children’s Hospital of Anhui Province from January 2018 to January 2021 were selected, they were divided into observation group and control group, with 40 cases in each group. The control group was treated with Aspirin and IVIG, and observation group was treated with Dipyridamole on the basis of control group. The clinical efficacy of two groups was compared; T lymphocyte subsets, prothrombin time (PT), thrombin time (TT), activated partial thromboplastin time (APTT), fibrinogen (Fbg) and the levels of serum tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP) were compared between two groups before and after treatment; the occurrence of adverse reactions during treatment was recorded. Results The total effective rate of observation group was higher than that of control group, and the difference was statistically significant (P < 0.05). After treatment, CD4+ and CD4+/CD8+ in observation group were lower than those before treatment, and observation group was lower than control group, and the differences were statistically significant (P < 0.05); CD8+ in both groups were higher than those before treatment, and observation group was higher than control group, and the differences were statistically significant (P < 0.05). After treatment, there were no significant differences in PT, TT, and APTT between two groups compared with before treatment (P > 0.05); the level of Fbg in two groups were lower than those before treatment, and observation group was lower than control group, and the differences were statistically significant (P < 0.05). After treatment, the levels of TNF-α, IL-6, and CRP in two groups were lower than those before treatment, and observation group was lower than control group, and the differences were statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between two groups (P > 0.05). Conclusion Dipyridamole combined with IVIG and Aspirin in the treatment of KD can effectively improve the immune function, coagulation function, and inflammation level of children, with high safety and significant effect, suggesting clinical application.
李虹媛 张辉 张建明▲. 双嘧达莫联合IVIG及阿司匹林治疗儿童川崎病的效果及对T淋巴细胞亚群、凝血功能和炎症因子水平的影响[J]. 中国医药导报, 2022, 19(2): 88-91.
LI Hongyuan ZHANG Hui ZHANG Jianming▲. Effect of Dipyridamole combined with IVIG and Aspirin in the treatment of children with Kawasaki disease and its effect on T lymphocyte subsets, coagulation function and inflammatory factor levels#br#. 中国医药导报, 2022, 19(2): 88-91.
[1] 赵有丽，刘彩霞.阿司匹林联合大剂量丙种球蛋白治疗小儿川崎病的疗效及对血清脑利钠肽指标的影响[J].川北医学院学报，2018，161（2）：28-30.
[2] 韦健霞，王青.强化抗血小板方案辅助丙种球蛋白对川崎病患儿近期疗效，症状缓解时间及炎性因子指标水平的影响[J].中国生化药物杂志，2019，15（5）：344-346.
[3] 王玉，马依晨，李艳，等.双嘧达莫治疗川崎病临床疗效及对患儿CRP、PCT等水平影响研究[J].陕西医学杂志，2018，47（12）：134-137.
[4] 李丹，冯媛，耿玲玲，等.小剂量甲基泼尼松龙联合静脉丙种球蛋白治疗静脉丙种球蛋白无反应型川崎病的疗效分析[J].中国全科医学，2019，22（4）：81-85.
[5] Ueharu K，Asano T，Fukunaga R，et al. A Case of Kawasaki Disease with Intussusception [J]. J Nippon Med Sch，2021，87（6）：346-349.
[6] 张慧玲.大剂量丙种球蛋白联合阿司匹林治疗川崎病患儿的临床效果[J].中国医药，2019，14（4）：107-110.
[7] 尹梅，田建宏，王海霞，等.双嘧达莫联合头孢呋辛对川崎病患儿WBC，PLT，ESR水平的影响[J].现代生物医学进展，2020，20（22）：4323-4326，4261.
[8] 杜忠东，于淼.小儿川崎病的临床诊断标准[J].中国临床医生杂志，2001，29（3）：30-31.
[9] 陈树宝.川崎病研究进展——第10届国际川崎病研讨会概况介绍[C]//第十七届全国小儿心血管疾病学术会议论文集.日本京都，2012：92-97.
[10] Isidori C，Sebastiani L，Esposito S. A Case of Incomplete and Atypical Kawasaki Disease Presenting with Retropharyngeal Involvement [J]. Int J Environ Res Public Health，2019，16（18）：3262-3265.
[11] 徐闪，何俊明.阿司匹林辅助丙种球蛋白治疗小儿川崎病的应用效果及其对预防冠状动脉病变的作用分析[J].中国妇幼保健，2021，37（1）：26-27.
[12] 王茹，戚昌丽.双嘧达莫联合丙种球蛋白及阿司匹林治疗川崎病疗效及对患儿免疫功能和凝血功能的影响[J].河北医学，2021，27（2）：317-321.
[13] Rauf A，Vijayan A，John ST，et al. Multisystem Inflammatory Syndrome with Features of Atypical Kawasaki Disease during COVID-19 Pandemic [J]. Indian J Pediatr，2020，87（9）：745-747.
[14] 何琳琳，李琴，刘定远，等.双嘧达莫辅助治疗川崎病患儿的疗效及对T淋巴细胞亚群，凝血功能影响[J].现代生物医学进展，2020，20（10）：1929-1932，1904.
[15] 孔慧君，郭旭丽.二联抗血小板方案治疗丙种球蛋白无反应川崎病的临床研究[J].国际儿科学杂志，2019，46（10）：769-772.
[16] Arslanoglu Aydin E，Demir S，Aydin O，et al. Pleural effusion as an atypical presentation of Kawasaki disease a case report and review of the literature [J]. J Med Case Rep，2019，13（1）：344-349.
[17] 张慎荣，周芳，邵启民.糖皮质激素联合丙种球蛋白治疗丙种球蛋白无反应型川崎病的临床疗效[J].中国现代医生，2021，59（18）：57-60.
[18] 邢前.血清白蛋白、血小板反应蛋白1及血小板反应蛋白2水平对川崎病患儿发生静脉注射免疫球蛋白抵抗的预测价值[J].广西医学，2019，29（16）：1023-1026.
[19] 吕玲.不同剂量静脉用丙种球蛋白或加甲泼尼龙治疗无反应川崎病患儿的临床疗效分析[J].深圳中西医结合杂志，2019，25（5）：111-112.
[20] Kuo HC，Lo MH，Hsieh KS，et al. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease [J]. PLoS One，2019，10（12）：4603-4607.
[21] 吴慧莲，陈金妮.肾上腺糖皮质激素联合乌司他丁治疗儿童川崎病患儿淋巴细胞亚群及预后的影响[J].中国地方病防治杂志，2020，49（1）：113，115.
[22] 沈新.不同剂量丙种球蛋白对川崎病患儿临床症状，炎性指标及冠状动脉损害的改善作用比较[J].现代中西医结合杂志，2019，22（14）：1538-1540.
[23] Furui S，Seki M，Minami T，et al. A case of Kawasaki disease complicated by acute disseminated encephalitis [J]. Pediatr Int，2020，62（7）：872-873.
[24] 王航政.丙种球蛋白与阿司匹林联合丹参注射液治疗川崎病临床研究[J].国际中医中药杂志，2019，38（12）：1083-1086.
[25] 韦海涛，汪希珂，陈林，等.不同剂量丙种球蛋白治疗丙种球蛋白无反应型川崎病患儿的临床疗效探讨[J].贵州医药，2019，43（8）：1285-1288.
[26] Blonz G，Lacroix S，Benbrik N，et al. Severe Late-Onset Kawasaki Disease Successfully Treated With Anakinra [J].J Clin Rheumatol，2020，26（2）：e42-e43.
京公网安备 11010502046598号